大约 30% 的 IV 期肺腺癌在诊断后 3 个月内死亡。铂类化疗=PBC和酪氨酸激酶抑制剂靶向治疗=TT等西医治疗可以改善预后。在中国，除了 PBC 和 TT 之外，还经常使用中药治疗 (TCM)。相当一部分患者拒绝西医治疗，只采用中医治疗。然而，后者对生存的影响尚不清楚。单独使用中医治疗的预后优于单独使用 PBC。在 TCM 中添加 PBC 或 TT 或两者 TT 可提高生存率。 在这项前瞻性观察性、非干预性研究中，对 1017 名连续首发 IV 期 NSCLC 患者进行了长达 10 年的随访，其中 261 名患者在 10 年内死于疾病 (DOD)。 3个月的时间被省略了，因为他们没有得到最佳的西医治疗。所有 218 例非腺癌也被省略，剩下 538 例 IV 期腺癌仅采用中药治疗 (n = 29)、单独治疗 PBC (N = 19) 以及中西医结合治疗 (299 例中药和 PBC、50 例中药和 TT、141 例) TCM 和 PBC 和 TT），并进行 3 - 120 个月的随访。使用疾病存活 (AWD) 和 DOD 作为终点来比较生存率。仅接受 TCM 治疗的患者的中位生存期比仅接受 PBC 的患者（17 个月和 10 个月）长 7 个月。接受TCM和PBC治疗的患者比单独接受TCM治疗的患者有更好的中位生存期（24个月），并且比单独接受PBC治疗的患者好得多。单独接受中药治疗的患者均未存活超过 54 个月，而 18% 的中药和 PBC 患者存活时间更长。在3-120个月的观察期内，中药和TT、中药和PBC和TT、中药和PBC的生存率没有差异，因此分为中药和西药。单纯PBC和单纯中药治疗的中位生存时间均低于中药和西医治疗的中位生存时间（p < 0.0001、10、17和27个月）。单独中药治疗的生存期至少3个月的肺IV期腺癌患者的中位生存时间与单独使用 PBC 治疗的患者相比，生存率显着提高。在中医中添加西药 PBC、TT 或两者可进一步改善预后。版权所有 © 2023。由 Elsevier GmbH 出版。

About 30% of pulmonary stage IV adenocarcinomas die within 3 months of diagnosis. Western medical treatments with Platinum-Based Chemotherapy=PBC and tyrosine-kinase inhibitors Targeted Therapy=TT can improve prognosis. In China, Traditional Chinese Medicine herbal treatments (TCM) are often used in addition to PBC and TT. A considerable number of patients refuse Western medical treatments and use TCM alone. However, the survival impact of the latter is unknown.Treatment with TCM alone is prognostically superior to PBC alone. Addition of PBC or TT or both TT to TCM improves survival.In this prospective observational, non-interventional study of 1017 consecutive first-onset stage IV NSCLC patients with up to 10 years follow-up, 261 who Died of Disease (DOD) within 3 months were omitted, as they never got the optimal Western medical therapies. All 218 non-adenocarcinomas were also omitted, leaving 538 stage IV adenocarcinomas treated by TCM alone (n = 29), PBC alone (N = 19) and TCM and other Western medical combinations (299 TCM and PBC, 50 TCM and TT, 141 TCM and PBC and TT) with 3 - 120 months follow-up. Survivals were compared using Alive with Disease (AWD) and DOD as endpoints.The patients treated only with TCM had 7 months better median survival than those that received PBC alone (17 and 10 months). The patients that received TCM and PBC had a better median survival (24 months) than TCM alone and much better than PBC alone. None of the patients that received TCM alone survived > 54 months, whereas 18% of TCM and PBC patients survived much longer. Over the observation period of 3 - 120 months, survivals of TCM and TT, TCM and PBC and TT, and TCM and PBC were not different and therefore grouped as TCM and Western medicines. Median survival times of PBC alone and TCM alone were lower than that of TCM and Western medical treatments (p < 0.0001, 10, 17 and 27 months).Pulmonary stage IV adenocarcinoma patients with at least 3 months survival, treated with TCM alone have a significantly better survival than those treated with PBC alone. Adding Western PBC, TT or both to TCM further improves prognosis.Copyright © 2023. Published by Elsevier GmbH.